SG11201408113QA - Mutational analysis of plasma dna for cancer detection - Google Patents

Mutational analysis of plasma dna for cancer detection

Info

Publication number
SG11201408113QA
SG11201408113QA SG11201408113QA SG11201408113QA SG11201408113QA SG 11201408113Q A SG11201408113Q A SG 11201408113QA SG 11201408113Q A SG11201408113Q A SG 11201408113QA SG 11201408113Q A SG11201408113Q A SG 11201408113QA SG 11201408113Q A SG11201408113Q A SG 11201408113QA
Authority
SG
Singapore
Prior art keywords
lllll
international
hong kong
sar
llll
Prior art date
Application number
SG11201408113QA
Other languages
English (en)
Inventor
Yuk-Ming Dennis Lo
Kwan Chee Chan
Wai Kwun Rossa Chiu
Peiyong Jiang
Original Assignee
Univ Hong Kong Chinese
Wai Kwun Rossa Chiu
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Hong Kong Chinese, Wai Kwun Rossa Chiu filed Critical Univ Hong Kong Chinese
Publication of SG11201408113QA publication Critical patent/SG11201408113QA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6827—Hybridisation assays for detection of mutation or polymorphism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J19/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
    • B01J19/0046—Sequential or parallel reactions, e.g. for the synthesis of polypeptides or polynucleotides; Apparatus and devices for combinatorial chemistry or for making molecular arrays
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1065—Preparation or screening of tagged libraries, e.g. tagged microorganisms by STM-mutagenesis, tagged polynucleotides, gene tags
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6806—Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C12Q1/6853—Nucleic acid amplification reactions using modified primers or templates
    • C12Q1/6855—Ligating adaptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G16B20/20—Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B30/00—ICT specially adapted for sequence analysis involving nucleotides or amino acids
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B30/00—ICT specially adapted for sequence analysis involving nucleotides or amino acids
    • G16B30/10—Sequence alignment; Homology search
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2525/00—Reactions involving modified oligonucleotides, nucleic acids, or nucleotides
    • C12Q2525/10—Modifications characterised by
    • C12Q2525/191—Modifications characterised by incorporating an adaptor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2535/00—Reactions characterised by the assay type for determining the identity of a nucleotide base or a sequence of oligonucleotides
    • C12Q2535/122—Massive parallel sequencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2537/00—Reactions characterised by the reaction format or use of a specific feature
    • C12Q2537/10—Reactions characterised by the reaction format or use of a specific feature the purpose or use of
    • C12Q2537/16—Assays for determining copy number or wherein the copy number is of special importance
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2537/00—Reactions characterised by the reaction format or use of a specific feature
    • C12Q2537/10—Reactions characterised by the reaction format or use of a specific feature the purpose or use of
    • C12Q2537/165—Mathematical modelling, e.g. logarithm, ratio
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2539/00—Reactions characterised by analysis of gene expression or genome comparison
    • C12Q2539/10—The purpose being sequence identification by analysis of gene expression or genome comparison characterised by
    • C12Q2539/107—Representational Difference Analysis [RDA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/166—Oligonucleotides used as internal standards, controls or normalisation probes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
    • Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation
SG11201408113QA 2012-06-21 2013-06-14 Mutational analysis of plasma dna for cancer detection SG11201408113QA (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201261662878P 2012-06-21 2012-06-21
US201261682725P 2012-08-13 2012-08-13
US201261695795P 2012-08-31 2012-08-31
US201261711172P 2012-10-08 2012-10-08
US13/801,748 US11261494B2 (en) 2012-06-21 2013-03-13 Method of measuring a fractional concentration of tumor DNA
PCT/IB2013/054898 WO2013190441A2 (en) 2012-06-21 2013-06-14 Mutational analysis of plasma dna for cancer detection

Publications (1)

Publication Number Publication Date
SG11201408113QA true SG11201408113QA (en) 2015-01-29

Family

ID=52274459

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201408113QA SG11201408113QA (en) 2012-06-21 2013-06-14 Mutational analysis of plasma dna for cancer detection
SG10201808217WA SG10201808217WA (en) 2012-06-21 2013-06-14 Mutational analysis of plasma dna for cancer detection

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG10201808217WA SG10201808217WA (en) 2012-06-21 2013-06-14 Mutational analysis of plasma dna for cancer detection

Country Status (19)

Country Link
US (3) US11261494B2 (es)
EP (3) EP2864501B1 (es)
JP (4) JP6371280B2 (es)
KR (7) KR102375645B1 (es)
CN (3) CN113151474A (es)
AU (4) AU2013278994C1 (es)
CA (2) CA2876327C (es)
DK (2) DK2864501T3 (es)
EA (2) EA202092900A3 (es)
ES (2) ES2894479T3 (es)
HK (3) HK1204013A1 (es)
HU (1) HUE056915T2 (es)
IL (5) IL298810B1 (es)
MX (3) MX360264B (es)
PT (1) PT3456843T (es)
SG (2) SG11201408113QA (es)
TW (4) TW202328458A (es)
WO (1) WO2013190441A2 (es)
ZA (1) ZA201409281B (es)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11168370B2 (en) 2015-02-10 2021-11-09 The Chinese University Of Hong Kong Detecting mutations for cancer screening

Families Citing this family (90)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8583380B2 (en) 2008-09-05 2013-11-12 Aueon, Inc. Methods for stratifying and annotating cancer drug treatment options
US11408031B2 (en) 2010-05-18 2022-08-09 Natera, Inc. Methods for non-invasive prenatal paternity testing
US11939634B2 (en) 2010-05-18 2024-03-26 Natera, Inc. Methods for simultaneous amplification of target loci
US9309556B2 (en) 2010-09-24 2016-04-12 The Board Of Trustees Of The Leland Stanford Junior University Direct capture, amplification and sequencing of target DNA using immobilized primers
KR20230141927A (ko) 2010-12-30 2023-10-10 파운데이션 메디신 인코포레이티드 종양 샘플의 다유전자 분석의 최적화
US9892230B2 (en) 2012-03-08 2018-02-13 The Chinese University Of Hong Kong Size-based analysis of fetal or tumor DNA fraction in plasma
US11261494B2 (en) 2012-06-21 2022-03-01 The Chinese University Of Hong Kong Method of measuring a fractional concentration of tumor DNA
US20150011396A1 (en) 2012-07-09 2015-01-08 Benjamin G. Schroeder Methods for creating directional bisulfite-converted nucleic acid libraries for next generation sequencing
US11913065B2 (en) 2012-09-04 2024-02-27 Guardent Health, Inc. Systems and methods to detect rare mutations and copy number variation
IL269097B2 (en) 2012-09-04 2024-01-01 Guardant Health Inc Systems and methods for detecting rare mutations and changes in number of copies
US10876152B2 (en) 2012-09-04 2020-12-29 Guardant Health, Inc. Systems and methods to detect rare mutations and copy number variation
US20160040229A1 (en) 2013-08-16 2016-02-11 Guardant Health, Inc. Systems and methods to detect rare mutations and copy number variation
US9822408B2 (en) 2013-03-15 2017-11-21 Nugen Technologies, Inc. Sequential sequencing
CN105518151B (zh) 2013-03-15 2021-05-25 莱兰斯坦福初级大学评议会 循环核酸肿瘤标志物的鉴别和用途
EP3068883B1 (en) 2013-11-13 2020-04-29 Nugen Technologies, Inc. Compositions and methods for identification of a duplicate sequencing read
CA2934822A1 (en) 2013-12-28 2015-07-02 Guardant Health, Inc. Methods and systems for detecting genetic variants
RU2717641C2 (ru) * 2014-04-21 2020-03-24 Натера, Инк. Обнаружение мутаций и плоидности в хромосомных сегментах
PT3543356T (pt) 2014-07-18 2021-10-04 Univ Hong Kong Chinese Análise dos padrões de metilação de tecidos em mistura de adn
EP4358097A1 (en) * 2014-07-25 2024-04-24 University of Washington Methods of determining tissues and/or cell types giving rise to cell-free dna, and methods of identifying a disease or disorder using same
JP6803327B2 (ja) * 2014-08-06 2020-12-23 ニューゲン テクノロジーズ， インコーポレイテッド 標的化されたシークエンシングからのデジタル測定値
PT3198026T (pt) * 2014-08-07 2020-01-16 Pharmassist Ltd Método de determinação do estado mutacional de pik3ca numa amostra
US11085084B2 (en) 2014-09-12 2021-08-10 The Board Of Trustees Of The Leland Stanford Junior University Identification and use of circulating nucleic acids
WO2016090273A1 (en) 2014-12-05 2016-06-09 Foundation Medicine, Inc. Multigene analysis of tumor samples
EP3502273B1 (en) 2014-12-12 2020-07-08 Verinata Health, Inc. Cell-free dna fragment
EP3240911B1 (en) * 2014-12-31 2020-08-26 Guardant Health, Inc. Detection and treatment of disease exhibiting disease cell heterogeneity and systems and methods for communicating test results
US10364467B2 (en) * 2015-01-13 2019-07-30 The Chinese University Of Hong Kong Using size and number aberrations in plasma DNA for detecting cancer
CA3234222A1 (en) * 2015-05-01 2016-11-10 Guardant Health, Inc. Diagnostic methods
WO2016183106A1 (en) 2015-05-11 2016-11-17 Natera, Inc. Methods and compositions for determining ploidy
CN104894268B (zh) * 2015-06-05 2018-02-09 上海美吉生物医药科技有限公司 定量样本中源自细胞凋亡的dna浓度的方法及其应用
JP6202659B2 (ja) * 2015-07-01 2017-09-27 学校法人慶應義塾 癌組織の不均一性マーカー及びその使用
JP2017016665A (ja) * 2015-07-03 2017-01-19 国立大学法人東北大学 配列のデータからの変異情報の選択方法、システム、及び、コンピュータプログラム
EP3739061B1 (en) 2015-07-20 2022-03-23 The Chinese University Of Hong Kong Methylation pattern analysis of haplotypes in tissues in dna mixture
IL305462A (en) 2015-07-23 2023-10-01 Univ Hong Kong Chinese DNA fragmentation pattern analysis suitable clean
US11319586B2 (en) * 2015-08-12 2022-05-03 The Chinese University Of Hong Kong Single-molecule sequencing of plasma DNA
WO2017035400A1 (en) 2015-08-25 2017-03-02 Nantomics, Llc Systems and methods for genetic analysis of metastases
SG11201805119QA (en) 2015-12-17 2018-07-30 Guardant Health Inc Methods to determine tumor gene copy number by analysis of cell-free dna
CN116640847A (zh) * 2016-02-02 2023-08-25 夸登特健康公司 癌症进化检测和诊断
US10095831B2 (en) 2016-02-03 2018-10-09 Verinata Health, Inc. Using cell-free DNA fragment size to determine copy number variations
KR101810528B1 (ko) * 2016-03-29 2017-12-21 한국과학기술원 단백질을 변화시키지 않는 암 돌연변이의 기능적 recurrence를 구하는 방법 및 장치
EP3443066A4 (en) * 2016-04-14 2019-12-11 Guardant Health, Inc. EARLY DETECTION METHODS FOR CANCER
GB2555765A (en) 2016-05-01 2018-05-16 Genome Res Ltd Method of detecting a mutational signature in a sample
CN105969856B (zh) * 2016-05-13 2019-11-12 万康源(天津)基因科技有限公司 一种单细胞外显子测序肿瘤体细胞突变检测方法
CN105969656B (zh) * 2016-05-13 2019-09-10 万康源(天津)基因科技有限公司 一种单细胞外显子测序肿瘤体细胞突变检测及分析平台
CN106355045B (zh) * 2016-08-30 2019-03-15 天津诺禾致源生物信息科技有限公司 一种基于扩增子二代测序小片段插入缺失检测的方法及装置
KR20210158870A (ko) * 2016-09-30 2021-12-31 가던트 헬쓰, 인크. 무세포 핵산의 다중-해상도 분석 방법
EP3535415A4 (en) 2016-10-24 2020-07-01 The Chinese University of Hong Kong TUMOR DETECTION METHODS AND SYSTEMS
GB201618485D0 (en) * 2016-11-02 2016-12-14 Ucl Business Plc Method of detecting tumour recurrence
WO2018090298A2 (en) * 2016-11-17 2018-05-24 Genomicare Biotechnology (Shanghai) Co. Ltd. Systems and methods for monitoring lifelong tumor evolution
CN109983134A (zh) 2016-11-30 2019-07-05 香港中文大学 尿液和其他样品中无细胞dna的分析
WO2018106884A1 (en) * 2016-12-08 2018-06-14 Life Technologies Corporation Methods for detecting mutation load from a tumor sample
CN106874710A (zh) * 2016-12-29 2017-06-20 安诺优达基因科技(北京)有限公司 一种用于利用肿瘤ffpe样本检测体细胞突变的装置
CN106845153A (zh) * 2016-12-29 2017-06-13 安诺优达基因科技(北京)有限公司 一种用于利用循环肿瘤dna样本检测体细胞突变的装置
TWI803477B (zh) 2017-01-25 2023-06-01 香港中文大學 使用核酸片段之診斷應用
US11342047B2 (en) * 2017-04-21 2022-05-24 Illumina, Inc. Using cell-free DNA fragment size to detect tumor-associated variant
JP7123975B2 (ja) * 2017-05-16 2022-08-23 ガーダント ヘルス， インコーポレイテッド 無細胞ｄｎａについての体細胞起源または生殖系列起源の識別
KR102145417B1 (ko) * 2017-05-24 2020-08-19 지니너스 주식회사 무세포 핵산으로부터 수득된 서열 분석 데이터에 대한 배경 대립인자의 빈도 분포를 생성하는 방법 및 이를 이용하여 무세포 핵산으로부터 변이를 검출하는 방법
AU2018305609B2 (en) 2017-07-26 2023-01-19 The Chinese University Of Hong Kong Enhancement of cancer screening using cell-free viral nucleic acids
WO2019055835A1 (en) * 2017-09-15 2019-03-21 The Regents Of The University Of California DETECTION OF SOMATIC MONONUCLEOTIDE VARIANTS FROM ACELLULAR NUCLEIC ACID WITH APPLICATION TO MINIMUM RESIDUAL DISEASE SURVEILLANCE
CA3075932A1 (en) * 2017-09-20 2019-03-28 Guardant Health, Inc. Methods and systems for differentiating somatic and germline variants
US20200265922A1 (en) * 2017-10-10 2020-08-20 Nantomics, Llc Comprehensive Genomic Transcriptomic Tumor-Normal Gene Panel Analysis For Enhanced Precision In Patients With Cancer
US11099202B2 (en) 2017-10-20 2021-08-24 Tecan Genomics, Inc. Reagent delivery system
CN111566225A (zh) * 2017-11-03 2020-08-21 夸登特健康公司 归一化肿瘤突变负荷
AU2018375785A1 (en) * 2017-11-30 2019-12-12 Illumina, Inc. Validation methods and systems for sequence variant calls
US20190249229A1 (en) * 2018-02-12 2019-08-15 Nant Holdings Ip, Llc Bam signatures from liquid and solid tumors and uses therefor
CN112218957A (zh) * 2018-04-16 2021-01-12 格里尔公司 用于确定在无细胞核酸中的肿瘤分数的系统及方法
CA3098321A1 (en) 2018-06-01 2019-12-05 Grail, Inc. Convolutional neural network systems and methods for data classification
EP3802878A1 (en) * 2018-06-04 2021-04-14 Guardant Health, Inc. Methods and systems for determining the cellular origin of cell-free nucleic acids
CN112752854A (zh) 2018-07-23 2021-05-04 夸登特健康公司 用于通过肿瘤分数和覆盖率调整肿瘤突变负荷的方法和系统
US20200143905A1 (en) * 2018-11-01 2020-05-07 Illumina, Inc. Methods and compositions for germline variant detection
US11581062B2 (en) 2018-12-10 2023-02-14 Grail, Llc Systems and methods for classifying patients with respect to multiple cancer classes
WO2020125709A1 (en) 2018-12-19 2020-06-25 The Chinese University Of Hong Kong Cell-free dna end characteristics
EP3899956A4 (en) * 2018-12-21 2022-11-23 Grail, LLC SYSTEMS AND METHODS OF USING FRAGMENT LENGTHS AS A CANCER PREDICTOR
CN109616198A (zh) * 2018-12-28 2019-04-12 陈洪亮 仅用于肝癌单一癌种筛查的特异甲基化检测位点组合的选取方法
CN109686414A (zh) * 2018-12-28 2019-04-26 陈洪亮 仅用于肝癌筛查的特异甲基化检测位点组合的选取方法
CN109817279B (zh) * 2019-01-18 2022-11-04 臻悦生物科技江苏有限公司 肿瘤突变负荷的检测方法、装置、存储介质及处理器
KR102381252B1 (ko) * 2019-02-19 2022-04-01 주식회사 녹십자지놈 혈중 무세포 dna 기반 간암 치료 예후예측 방법
CN109841265B (zh) * 2019-02-22 2021-09-21 清华大学 使用片段化模式确定血浆游离核酸分子组织来源的方法和系统及应用
CN109920480B (zh) * 2019-03-14 2020-02-21 深圳市海普洛斯生物科技有限公司 一种校正高通量测序数据的方法和装置
CN111755075B (zh) * 2019-03-28 2023-09-29 深圳华大生命科学研究院 对免疫组库高通量测序样本间序列污染进行过滤的方法
US20200392584A1 (en) * 2019-05-17 2020-12-17 Ultima Genomics, Inc. Methods and systems for detecting residual disease
CN111223525A (zh) * 2020-01-07 2020-06-02 广州基迪奥生物科技有限公司 一种肿瘤外显子测序数据分析方法
US11211144B2 (en) 2020-02-18 2021-12-28 Tempus Labs, Inc. Methods and systems for refining copy number variation in a liquid biopsy assay
US11211147B2 (en) 2020-02-18 2021-12-28 Tempus Labs, Inc. Estimation of circulating tumor fraction using off-target reads of targeted-panel sequencing
US11475981B2 (en) 2020-02-18 2022-10-18 Tempus Labs, Inc. Methods and systems for dynamic variant thresholding in a liquid biopsy assay
EP4364147A1 (en) * 2021-06-30 2024-05-08 Memorial Sloan-Kettering Cancer Center Detection of somatic mutational signatures from whole genome sequencing of cell-free dna
KR20230085239A (ko) * 2021-12-06 2023-06-14 주식회사 지씨지놈 혈중 무세포 dna 기반 유방암 치료 예후예측 방법
CN115064212B (zh) * 2022-06-24 2023-03-14 哈尔滨星云生物信息技术开发有限公司 基于wgs数据的预设区域人群肿瘤特异突变识别方法
WO2024003936A1 (en) 2022-06-29 2024-01-04 Raman Govindarajan Method for detecting cancer susceptibility, early detection and predicting cancer behaviour
KR20240051739A (ko) * 2022-10-13 2024-04-22 인하대학교 산학협력단 cfDNA의 구조 변이 서열 검출을 통한 미세잔존질환 진단 방법
CN117012274B (zh) * 2023-10-07 2024-01-16 北京智因东方转化医学研究中心有限公司 基于高通量测序识别基因缺失的装置

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ20013527A3 (cs) 1999-04-02 2002-10-16 Corixa Corporation Sloučeniny a způsoby pro terapii a diagnostiku karcinomu plic
US20030219765A1 (en) 2000-03-23 2003-11-27 Jose Costa Methods for evaluating cancer risk
WO2003062441A1 (en) 2002-01-18 2003-07-31 Genzyme Corporation Methods for fetal dna detection and allele quantitation
AU2003241401B8 (en) 2002-05-10 2009-08-06 City Of Hope Pyrophosphorolysis activated polymerization (PAP)
US7704687B2 (en) 2002-11-15 2010-04-27 The Johns Hopkins University Digital karyotyping
US20060188889A1 (en) * 2003-11-04 2006-08-24 Christopher Burgess Use of differentially expressed nucleic acid sequences as biomarkers for cancer
AU2004217872B2 (en) 2003-03-05 2010-03-25 Genetic Technologies Limited Identification of fetal DNA and fetal cell markers in maternal plasma or serum
PL201608B1 (pl) 2003-06-13 2009-04-30 Cezary Cybulski Sposób i zestaw do wykrywania wysokiej genetycznie uwarunkowanej predyspozycji do raka prostaty oraz zastosowanie zmiany germinalnej w obrębie genu NBS1
DE60328193D1 (de) 2003-10-16 2009-08-13 Sequenom Inc Nicht invasiver Nachweis fötaler genetischer Merkmale
WO2005108621A1 (en) 2004-04-30 2005-11-17 Yale University Methods and compositions for cancer diagnosis
AU2006224971B2 (en) * 2005-03-18 2009-07-02 Boston University A method for the detection of chromosomal aneuploidies
US20070122823A1 (en) 2005-09-01 2007-05-31 Bianchi Diana W Amniotic fluid cell-free fetal DNA fragment size pattern for prenatal diagnosis
EP3591068A1 (en) 2006-02-02 2020-01-08 The Board of Trustees of the Leland Stanford Junior University Non-invasive fetal genetic screening by digital analysis
AU2007220991C1 (en) 2006-02-28 2013-08-15 University Of Louisville Research Foundation Detecting fetal chromosomal abnormalities using tandem single nucleotide polymorphisms
WO2008024009A1 (fr) 2006-08-15 2008-02-28 Institut Molekulyarnoi Genetiki Rossiiskoi Akademii Nauk (Img Ran) Niveau de transcription du gène timp3 utilisé en tant que marqueur servant à diagnostiquer le cancer du poumon non à petites cellules
EP2535425A1 (en) 2007-05-25 2012-12-19 Decode Genetics EHF. Variantes génétiques sur les chr 10q26 utilisées comme marqueurs dans l'évaluation, le diagnostic, le pronostic et le traitement d'un risque de cancer du sein
US20090029377A1 (en) 2007-07-23 2009-01-29 The Chinese University Of Hong Kong Diagnosing fetal chromosomal aneuploidy using massively parallel genomic sequencing
US20090053719A1 (en) 2007-08-03 2009-02-26 The Chinese University Of Hong Kong Analysis of nucleic acids by digital pcr
US20100041048A1 (en) 2008-07-31 2010-02-18 The Johns Hopkins University Circulating Mutant DNA to Assess Tumor Dynamics
CA3069081C (en) * 2008-09-20 2023-05-23 The Board Of Trustees Of The Leland Stanford Junior University Noninvasive diagnosis of fetal aneuploidy by sequencing
US20100136560A1 (en) 2008-12-02 2010-06-03 The Johns Hopkins University Integrated Analyses of Breast and Colorectal Cancers
JP2012521772A (ja) 2009-03-31 2012-09-20 オリディス・バイオマーカーズ・ゲーエムベーハー 癌の診断及び癌処置のモニタリングのための方法
US20120208711A1 (en) 2009-10-02 2012-08-16 Centre For Addiction And Mental Health Method for Analysis of DNA Methylation Profiles of Cell-Free Circulating DNA in Bodily Fluids
WO2011053790A2 (en) 2009-10-30 2011-05-05 Fluidigm Corporation Assay of closely linked targets in fetal diagnosis and coincidence detection assay for genetic analysis
FI3783110T3 (fi) 2009-11-05 2023-03-02 Fetaalisen genomin analyysi maternaalisesta biologisesta näytteestä
BR112012010708A2 (pt) 2009-11-06 2016-03-29 Univ Hong Kong Chinese método para realizar diagnóstico pré-natal, e, produto de programa de computador
GB0922006D0 (en) 2009-12-17 2010-02-03 Genome Res Ltd Diagnostic
ES2534758T3 (es) 2010-01-19 2015-04-28 Verinata Health, Inc. Métodos de secuenciación en diagnósticos prenatales
CA2786564A1 (en) 2010-01-19 2011-07-28 Verinata Health, Inc. Identification of polymorphic sequences in mixtures of genomic dna by whole genome sequencing
EP2536854B1 (en) 2010-02-18 2017-07-19 The Johns Hopkins University Personalized tumor biomarkers
EP2426217A1 (en) 2010-09-03 2012-03-07 Centre National de la Recherche Scientifique (CNRS) Analytical methods for cell free nucleic acids and applications
CN105243295B (zh) 2010-11-30 2018-08-17 香港中文大学 与癌症相关的遗传或分子畸变的检测
KR101974492B1 (ko) 2011-07-26 2019-05-02 베리나타 헬스, 인코포레이티드 샘플 중 상이한 이수성의 존재 또는 부재를 결정하는 방법
ES2886508T3 (es) 2011-10-06 2021-12-20 Sequenom Inc Métodos y procedimientos para la evaluación no invasiva de variaciones genéticas
US10214775B2 (en) 2011-12-07 2019-02-26 Chronix Biomedical Prostate cancer associated circulating nucleic acid biomarkers
US9892230B2 (en) 2012-03-08 2018-02-13 The Chinese University Of Hong Kong Size-based analysis of fetal or tumor DNA fraction in plasma
US9862995B2 (en) 2012-03-13 2018-01-09 Abhijit Ajit Patel Measurement of nucleic acid variants using highly-multiplexed error-suppressed deep sequencing
US11261494B2 (en) 2012-06-21 2022-03-01 The Chinese University Of Hong Kong Method of measuring a fractional concentration of tumor DNA
IL269097B2 (en) 2012-09-04 2024-01-01 Guardant Health Inc Systems and methods for detecting rare mutations and changes in number of copies
CA2902207A1 (en) 2013-02-21 2014-08-28 Toma Biosciences, Inc. Methods, compositions, and kits for nucleic acid analysis
WO2014145078A1 (en) 2013-03-15 2014-09-18 Verinata Health, Inc. Generating cell-free dna libraries directly from blood
US10174375B2 (en) 2013-09-20 2019-01-08 The Chinese University Of Hong Kong Sequencing analysis of circulating DNA to detect and monitor autoimmune diseases
US10262755B2 (en) 2014-04-21 2019-04-16 Natera, Inc. Detecting cancer mutations and aneuploidy in chromosomal segments
EP4358097A1 (en) 2014-07-25 2024-04-24 University of Washington Methods of determining tissues and/or cell types giving rise to cell-free dna, and methods of identifying a disease or disorder using same

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11168370B2 (en) 2015-02-10 2021-11-09 The Chinese University Of Hong Kong Detecting mutations for cancer screening

Also Published As

Publication number Publication date
AU2017204558A1 (en) 2017-07-27
IL311127A (en) 2024-04-01
JP2021191280A (ja) 2021-12-16
CA2876327A1 (en) 2013-12-27
KR20240049635A (ko) 2024-04-16
EA037292B1 (ru) 2021-03-05
KR101884909B1 (ko) 2018-08-02
JP7408161B2 (ja) 2024-01-05
AU2020200122A1 (en) 2020-01-30
KR102237923B1 (ko) 2021-04-08
IL268645A (en) 2019-10-31
IL298810A (en) 2023-02-01
SG10201808217WA (en) 2018-10-30
HK1246830A1 (zh) 2018-09-14
KR20230052998A (ko) 2023-04-20
EP2864501A4 (en) 2016-03-16
CN104662168A (zh) 2015-05-27
TWI786428B (zh) 2022-12-11
HK1205533A1 (en) 2015-12-18
AU2022209294A1 (en) 2022-08-25
MX360264B (es) 2018-10-26
AU2017204558B2 (en) 2019-10-10
JP6930948B2 (ja) 2021-09-01
ZA201409281B (en) 2017-08-30
CN107779506B (zh) 2022-07-15
KR20210040464A (ko) 2021-04-13
IL278867A (en) 2021-01-31
AU2013278994A1 (en) 2015-01-29
IL298810B1 (en) 2024-04-01
AU2013278994B2 (en) 2017-04-06
EA202092900A2 (ru) 2021-03-31
CA2876327C (en) 2020-09-29
US11261494B2 (en) 2022-03-01
PT3456843T (pt) 2021-10-26
EP3456843B1 (en) 2021-07-28
KR20200035507A (ko) 2020-04-03
JP2015527057A (ja) 2015-09-17
EP3456843A1 (en) 2019-03-20
IL278867B2 (en) 2023-05-01
HUE056915T2 (hu) 2022-03-28
AU2013278994C1 (en) 2019-12-12
KR102096611B1 (ko) 2020-04-02
TW201920952A (zh) 2019-06-01
IL235967B (en) 2019-09-26
JP2024026360A (ja) 2024-02-28
TWI636255B (zh) 2018-09-21
TW202122796A (zh) 2021-06-16
ES2894479T3 (es) 2022-02-14
EP3919627A1 (en) 2021-12-08
MX2023001154A (es) 2023-02-22
JP2018191640A (ja) 2018-12-06
KR20150032708A (ko) 2015-03-27
CN104662168B (zh) 2017-12-05
TWI803505B (zh) 2023-06-01
DK2864501T3 (en) 2018-11-05
EP2864501B1 (en) 2018-08-08
KR102656030B1 (ko) 2024-04-08
DK3456843T3 (da) 2021-10-25
TW201403066A (zh) 2014-01-16
MX2014016058A (es) 2015-04-10
KR20180088922A (ko) 2018-08-07
ES2687847T3 (es) 2018-10-29
JP6371280B2 (ja) 2018-08-08
CN107779506A (zh) 2018-03-09
AU2020200122B2 (en) 2022-05-19
EP2864501A2 (en) 2015-04-29
EA201500027A1 (ru) 2015-05-29
EA202092900A3 (ru) 2021-06-30
US20180202003A1 (en) 2018-07-19
WO2013190441A3 (en) 2014-02-27
TW202328458A (zh) 2023-07-16
KR20220038181A (ko) 2022-03-25
CA3080937A1 (en) 2013-12-27
KR102375645B1 (ko) 2022-03-17
US20140100121A1 (en) 2014-04-10
KR102521842B1 (ko) 2023-04-14
HK1204013A1 (en) 2015-11-06
IL235967A0 (en) 2015-01-29
MX2018013085A (es) 2021-11-16
CN113151474A (zh) 2021-07-23
US20190264291A1 (en) 2019-08-29
IL278867B1 (en) 2023-01-01
WO2013190441A2 (en) 2013-12-27

Similar Documents

Publication Publication Date Title
SG11201408113QA (en) Mutational analysis of plasma dna for cancer detection
SG11201408002TA (en) Multi-parameter diabetes risk evaluations
SG11201908564RA (en) Devices, processes, and systems for determination of nucleic acid sequence, expression, copy number, or methylation changes using combined nuclease, ligase, polymerase, and sequencing reactions
SG11201909652WA (en) Neoantigen identification, manufacture, and use
SG11201903509QA (en) Methods and systems for tumor detection
SG11201806595UA (en) Using cell-free dna fragment size to determine copy number variations
SG11201407803TA (en) Nmr measurements of glyca
SG11201903158RA (en) Methods for cell label classification
SG11201909205YA (en) Immunoconjugates of an anti-pd-1 antibody with a mutant il-2 or with il-15
SG11201806432PA (en) Methods for assessing risk of developing colorectal cancer
SG11201407668XA (en) Method and device for detecting an analyte in a body fluid
SG11201908240YA (en) Methods for evaluating tumor cell spheroids using 3d microfluidic cell culture device
SG11201810694WA (en) Use of biomarkers in determining susceptibility to disease treatment
SG11201805420SA (en) Antibodies and conjugates thereof
SG11201809317VA (en) Methods for classifying patients with a solid cancer
SG11201901371XA (en) Methods for the detection of genomic copy changes in dna samples
SG11201903346QA (en) Gestational age assessment by methylation and size profiling of maternal plasma dna
SG11201407483YA (en) Compositions and methods for modulating smn gene family expression
SG11201408385TA (en) Methods of detecting diseases or conditions
SG11201806609TA (en) Cancer evolution detection and diagnostic
SG11201407702XA (en) Methods and compositions for rna-directed target dna modification and for rna-directed modulation of transcription
SG11201408434QA (en) Targeted rna-seq methods and materials for the diagnosis of prostate cancer
SG11201407710VA (en) Compositions comprising short-acting benzodiazepines
SG11201407660SA (en) Systems and methods for detection of particles in a beneficial agent
SG11201805600VA (en) Deep sequencing profiling of tumors